Sudeep Pharma Limited shareholders approved the company’s audited financial statements for FY26, a dividend declaration, and a new Employee Stock Option Scheme (ESOP) during its 37th Annual General Meeting held on August 4, 2026. The meeting also saw the adoption of new Articles of Association and the appointment of Mr. Milin Mehta as a Non-Executive Director. While promoter support was unanimous across all resolutions, public institutional investors voted against the ESOP scheme, though it passed with overall majority support.

The proceedings were conducted via Video Conferencing/Other Audio-Visual Means (VC/OAVM) in compliance with Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Mr. Hemang Mehta of H. M. Mehta & Associates served as the scrutinizer, submitting his consolidated report on August 5, 2026. A total of 103,015,735 votes were polled out of 112,948,625 shares held by shareholders on the record date of July 28, 2026, representing a 91.2% turnout.

Voting Results and Key Resolutions

Shareholders approved all ordinary and special resolutions put forth by the Board. The financial statements for the fiscal year ended March 31, 2026, along with the reports of the Board and Auditors, were adopted with near-unanimous support. The resolution to declare a dividend on equity shares for FY26 also passed with 100% support from promoters and public institutions, with only 29 votes cast against it by non-institutional public shareholders.

ESOP Scheme and Governance Changes

The most notable divergence in voting occurred regarding the 'Sudeep Pharma Employee Stock Option Scheme 2025'. This special resolution, which allows for the grant of options to employees of the company, its subsidiaries, and group companies, received 96.01% overall support. However, while promoter shareholders voted unanimously in favor, public institutional investors voted against the scheme with 25.39% opposition (4,107,790 votes against out of 16,179,103 polled). Non-institutional public shareholders largely supported the measure with 99.99% approval.

Additionally, shareholders approved a change in the remuneration of Mr. Ajay Shrirang Kandelkar, Whole Time Director, effective April 1, 2026, with 99.99% support. The new Articles of Association were adopted with 99.17% support, facing minor opposition from public institutional investors (0.83% against). Mr. Ajay Shrirang Kandelkar was also re-appointed as a director retiring by rotation.

Scrutinizer’s Report Details

The scrutinizer’s report confirmed that remote e-voting was open from August 1 to August 3, 2026. Forty-four members attended the physical/virtual meeting. No votes were declared invalid. The report highlights that the promoter group holds 86,012,797 shares, constituting the majority of the voting power, which secured the passage of all resolutions despite dissent from certain institutional blocks on governance-related special resolutions.

Sudeep Pharma reported a 29.8% year-on-year increase in consolidated net profit for the first quarter of FY26, reaching ₹405.87 lakh. The Vadodara-based pharmaceutical company saw its total income from operations rise 26% to ₹1,637.16 lakh, driven by robust demand across its product portfolio. Standalone results mirrored this growth trajectory, with net profit climbing 34% to ₹338.29 lakh against a revenue backdrop of ₹1,154.84 lakh.

The Board of Directors approved the unaudited financial results at its meeting held on August 4, 2026. The results were reviewed by the Audit Committee and filed with the stock exchanges pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Chairman and Managing Director Sujit Jaysukh Bhayani signed off on the financial statement, which is also available on the company’s website.

Financial Performance

The company’s consolidated earnings per share (EPS) stood at ₹3.59 for the quarter ended June 30, 2026, up from ₹2.84 in the corresponding period last year. Diluted EPS remained unchanged at ₹3.59. For the full fiscal year FY26, basic EPS was ₹15.50.

Standalone revenue from operations increased to ₹1,154.84 lakh from ₹867.94 lakh in Q1FY25. The standalone profit before tax rose to ₹454.08 lakh from ₹338.27 lakh, reflecting improved operational efficiency and cost management during the period.

What the Numbers Show

The divergence between standalone and consolidated profit growth highlights the contribution of subsidiaries or associates to the bottom line. While standalone profit grew by 34%, consolidated profit grew by 30%, suggesting that while core operations are expanding rapidly, associated entities may have faced margin pressures or lower growth rates compared to the previous quarter. The consistent rise in both top-line and bottom-line figures indicates sustained market demand for Sudeep Pharma’s offerings without significant one-time gains driving the result.